Safety and Efficacy of Rivaroxaban in Patients With Car Devices: Observations From the ROCKET AF Trial

Journal of the American Heart Association

DOI: 10.1161/jaha.116.004663

Citation Report

#	Article	IF	Citations
1	Management of Device Infections. Cardiac Electrophysiology Clinics, 2018, 10, 153-162.	1.2	9
2	Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation. American Journal of Therapeutics, 2019, 26, e679.	1.1	4
3	Rivaroxaban Ameliorates Angiotensin II-Induced Cardiac Remodeling by Attenuating TXNIP/Trx2 Interaction in KKAy Mice. Thrombosis Research, 2020, 193, 45-52.	2.9	13
4	Current Strategies to Minimize Postoperative Hematoma Formation in Patients Undergoing Cardiac Implantable Electronic Device Implantation: A Review. Heart Rhythm, 2021, 18, 641-650.	3.8	12
5	Non-Vitamin K Antagonists and Cardiac Implantable Electronic Devices. , 2021, .		0
6	Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: A Position Paper From the ESC Working Group on Thrombosis, in Collaboration With the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. Europace, 2022, 24, 1844-1871.	8.4	62
7	Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper. Thrombosis and Haemostasis, 2022, 122, 1625-1652.	4.6	110
8	Periprocedural Anticoagulation Therapy in Patients Undergoing Micra Leadless Pacemaker Implantation. International Journal of Cardiology, 2023, 371, 221-225.	3.2	2
9	Anticoagulant Therapy During Cardiovascular Implantable Electronic Device Procedures. Postepy W Kardiologii Interwencyjnej, 2023, 19, 99-112.	1.1	1